期刊文献+

In vitro study of micro-dystrophin gene-modified mesenchymal stem cells

In vitro study of micro-dystrophin gene-modified mesenchymal stem cells
下载PDF
导出
摘要 BACKGROUND: Studies have shown that the transplantation of mesenchymal stem cells (MSCs) improves dystrophin expression in muscle cell membrane of mdx mice and plays a role in ameliorating sport injuries to the myocyte. In addition, dystrophin gene plasmid injection exhibits therapeutic effect in mdx mice. However, these two methods exhibit shortcomings, such as low rate of post-transplantation expression. Therefore, the present study determined the combinatorial effects of these two methods. OBJECTIVE: To transfect and observe effects of pSL139 plasmid carrying the micro-dystrophin gene into MSCs, as well as in vitro micro-dystrophin gene expression in transfected MSCs. DESIGN, TIME AND SETTING: A comparative, molecular biology study was performed at the Laboratory of Tissue Engineering, West China Medical Center, Sichuan University from March 2007 to February 2008. MATERIALS: The pSL139 plasmid was cloned and provided by the Department of Neurology, Washington University, USA. Lipofectamine 2000 was purchased from Invitrogen, USA. Mouse anti-human dystrophin N-based terminal monoclonal antibody was purchased from Chemicon, USA. METHODS: Differential velocity adherent technique and density gradient centrifugation were combined to separate and culture MSCs from C57/BL10 mice. The cells were induced to trans-differentiate into osteoblasts. Subsequently, the Lipofectamine 2000 method was used to mediate transfection of plasmid pSL139 into third generation MSCs. MAIN OUTCOME MEASURES: Semi-quantitative reverse transcription polymerase-chain reaction and immunofluorescence were respectively employed to detect micro-dystrophin mRNA and protein expressions in MSCs. RESULTS: At 48 hours after MSC transfection with plasmid pSL139, a 379-kb target band was observed by agarose gel electrophoresis. Immunofluorescence revealed micro-dystrophin expression up to 45%-55%. CONCLUSION: Micro-dystrophin mRNA and protein were highly expressed in pSL139-transfected MSCs, which provided a method for efficient expr BACKGROUND: Studies have shown that the transplantation of mesenchymal stem cells (MSCs) improves dystrophin expression in muscle cell membrane of mdx mice and plays a role in ameliorating sport injuries to the myocyte. In addition, dystrophin gene plasmid injection exhibits therapeutic effect in mdx mice. However, these two methods exhibit shortcomings, such as low rate of post-transplantation expression. Therefore, the present study determined the combinatorial effects of these two methods. OBJECTIVE: To transfect and observe effects of pSL139 plasmid carrying the micro-dystrophin gene into MSCs, as well as in vitro micro-dystrophin gene expression in transfected MSCs. DESIGN, TIME AND SETTING: A comparative, molecular biology study was performed at the Laboratory of Tissue Engineering, West China Medical Center, Sichuan University from March 2007 to February 2008. MATERIALS: The pSL139 plasmid was cloned and provided by the Department of Neurology, Washington University, USA. Lipofectamine 2000 was purchased from Invitrogen, USA. Mouse anti-human dystrophin N-based terminal monoclonal antibody was purchased from Chemicon, USA. METHODS: Differential velocity adherent technique and density gradient centrifugation were combined to separate and culture MSCs from C57/BL10 mice. The cells were induced to trans-differentiate into osteoblasts. Subsequently, the Lipofectamine 2000 method was used to mediate transfection of plasmid pSL139 into third generation MSCs. MAIN OUTCOME MEASURES: Semi-quantitative reverse transcription polymerase-chain reaction and immunofluorescence were respectively employed to detect micro-dystrophin mRNA and protein expressions in MSCs. RESULTS: At 48 hours after MSC transfection with plasmid pSL139, a 379-kb target band was observed by agarose gel electrophoresis. Immunofluorescence revealed micro-dystrophin expression up to 45%-55%. CONCLUSION: Micro-dystrophin mRNA and protein were highly expressed in pSL139-transfected MSCs, which provided a method for efficient expr
出处 《Neural Regeneration Research》 SCIE CAS CSCD 2010年第7期496-501,共6页 中国神经再生研究(英文版)
基金 the National Natural Science Foundation of China for Young Scholars, No. 0040205401040
关键词 Duchenne muscular dystrophy mesenchymal stem cells micro-dystrophin gene modification Duchenne muscular dystrophy mesenchymal stem cells micro-dystrophin gene modification
  • 相关文献

参考文献4

二级参考文献30

  • 1李和伟,王志永,刘彤华.一种改进的质粒DNA提取及回收方法[J].基础医学与临床,1995,15(1):77-78. 被引量:6
  • 2赵振芬,刘桂永,沈瑞忠,袁世山.直接用酚和氯仿快速提取质粒[J].生物技术,1995,5(6):32-33. 被引量:7
  • 3贺竹梅,刘秋云.一种提取质粒DNA的改良方法[J].生物技术,1996,6(1):37-38. 被引量:22
  • 4邓宁.重组质粒DNA的提取和纯化方法研究[J].黄淮学刊(自然科学版),1996,12(4):61-63. 被引量:2
  • 5Hoffman EP, Brown RH, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell, 1987, 51:919-928. 被引量:1
  • 6Kapsa R, Kornberg AJ, Byrne E. Novel therapies for Duchenne muscular dystrophy. Lancet Neurol, 2003, 2: 299-310. 被引量:1
  • 7Romero NB, Braun S, Benveniste O, et al. Phase Ⅰ study of dystrophin plasmid-based gene therapy in Duchenne/Becker muscular dystrophy. Hum Gene Ther, 2004, 15 : 1065-1076. 被引量:1
  • 8Vilquin JT, Kennel PF, Patutneau-Jouas M, et al. Electrotransfer of naked DNA in the skeletal muscles of animal models of muscular dystrophies. Gene Ther, 2001, 8:1097-1107. 被引量:1
  • 9Liu F, Nishikawa M, Clemens PR, et el. Transfer of full-length DMD to the diaphragm muscle of DMD (mdx/mdx) mice through systemic administration of plasmid DNA. Mol Ther, 2001, 4:45-51. 被引量:1
  • 10Hang KW, Nishikawa M, Liu F, et al. Restoration of dystrophin expression in mdx miee by intravascular injection of naked DNA containing full- length dystrophin cDNA. Gene Ther, 2004, 11:901-908. 被引量:1

共引文献85

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部